Erin C. Boone

Erin C. Boone

Auto-generated profile, based on publicly available information

Erin C. Boone

Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation Children’s Mercy Kansas City Kansas City Missouri USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Laura B. RamseyLaura B. Ramsey
Laura B. Ramsey
LGLi Gong
Li Gong
SLSeung‐Been Lee
Seung‐Been Lee
JWJonathan B. Wagner
Jonathan B. Wagner
XZXujia Zhou
Xujia Zhou
AGAndrea Gaedigk
Andrea Gaedigk

5 February 2022 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
AGAndrea Gaedigk
Andrea Gaedigk
EBErin C. Boone
Erin C. Boone
SSSteven E. Scherer
Steven E. Scherer
SLSeung-Been Lee
Seung-Been Lee
INIbrahim Numanagić
Ibrahim Numanagić
LKLisa V. Kalman
Lisa V. Kalman

10 January 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
ATAmy J. Turner
Amy J. Turner
CHCyrine E. Haidar
Cyrine E. Haidar
WYWenjian Yang
Wenjian Yang
EBErin C. Boone
Erin C. Boone
SOSteven M. Offer
Steven M. Offer
AGAndrea Gaedigk
Andrea Gaedigk
The DPYD gene encodes dihydropyrimidine dehydrogenase, the rate‐limiting enzyme for the metabolism of fluoropyrimidines 5‐fluorouracil and capecitabine. Genetic variants in DPYD have been associated with altered enzyme activity, therefore accurate detection and interpretation is critical to predict metabolizer status for individualized fluoropyrimidine therapy. The most commonly observed deleterious variation is the causal variant linked to the previously described HapB3 haplotype, c.1129‐5923C>G (rs75017182) in intron 10, which introduces a cryptic splice site. A benign synonymous variant in exon 11, c.1236G>A (rs56038477) is also linked to HapB3 and is commonly used for testing. Previously, these single‐nucleotide polymorphisms (SNPs) have been reported to be in perfect linkage disequilibrium (LD); therefore, c.1236G>A is often utilized as a proxy for the function‐altering intronic variant. Clinical genotyping of DPYD identified a patient who had c.1236G>A, but not c.1129‐5923C>G, suggesting that these two SNPs may not be in perfect LD, as previously assumed. Additional individuals with c.1236G>A, but not c.1129‐5923C>G, were identified in the Children's Mercy Data Warehouse and the All of Us Research Program version 7 cohort substantiating incomplete SNP linkage. Consequently, testing only c.1236G>A can generate false‐positive results in some cases and lead to suboptimal dosing that may negatively impact patient therapy and prospect of survival. Our data show that DPYD genotyping should include the functional variant c.1129‐5923C>G, and not the c.1236G>A proxy, to accurately predict DPD activity.

2 August 2022 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
VPVictoria Pratt
Victoria Pratt
WWWendy Y. Wang
Wendy Y. Wang
EBErin C. Boone
Erin C. Boone
UBUlrich Broeckel
Ulrich Broeckel
NCNeal Cody
Neal Cody
LKLisa V. Kalman
Lisa V. Kalman

11 August 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
Pablo ZubiaurPablo Zubiaur
Pablo Zubiaur
PSPaula Soria-Chacartegui
Paula Soria-Chacartegui
EBErin C. Boone
Erin C. Boone
BPBhagwat Prasad
Bhagwat Prasad
JDJean Dinh
Jean Dinh
AGAndrea Gaedigk
Andrea Gaedigk
A novel haplotype composed of two non‐coding variants, CYP2C18 NM_000772.3:c.*31T (rs2860840) and NM_000772.2:c.819+2182G (rs11188059), referred to as “CYP2C:TG,” was recently associated with ultrarapid metabolism of various CYP2C19 substrates. As the underlying mechanism and clinical relevance of this effect remain uncertain, we analyzed existing in vivo and in vitro data to determine the magnitude of the CYP2C:TG haplotype effect. We assessed variability in pharmacokinetics of CYP2C19 substrates, including citalopram, sertraline, voriconazole, omeprazole, pantoprazole, and rabeprazole in 222 healthy volunteers receiving one of these six drugs. We also determined its impact on CYP2C8, CYP2C9, CYP2C18, and CYP2C19 protein abundance in 135 human liver tissue samples, and on CYP2C18/CYP2C19 activity in vitro using N‐desmethyl atomoxetine formation. No effects were observed according to CYP2C:TG haplotype or to CYP2C19*1+TG alleles (i.e., CYP2C19 alleles containing the CYP2C:TG haplotype). In contrast, CYP2C19 intermediate (e.g., CYP2C19*1/*2) and poor metabolizers (e.g., CYP2C19*2/*2) showed significantly higher exposure in vivo, lower CYP2C19 protein abundance in human liver microsomes, and lower activity in vitro compared with normal, rapid (i.e., CYP2C19*1/*17), and ultrarapid metabolizers (i.e., CYP2C19*17/*17). Moreover, a tendency toward lower exposure was observed in ultrarapid metabolizers compared with rapid metabolizers and normal metabolizers. Furthermore, when the CYP2C19*17 allele was present, CYP2C18 protein abundance was increased suggesting that genetic variation in CYP2C19 may be relevant to the overall metabolism of certain drugs by regulating not only its expression levels, but also those of CYP2C18. Considering all available data, we conclude that there is insufficient evidence supporting clinical CYP2C:TG testing to inform drug therapy.

13 August 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
Pablo ZubiaurPablo Zubiaur
Pablo Zubiaur
Cristina Rodriguez-AntonaCristina Rodriguez-Antona
Cristina Rodriguez-Antona
EBErin C. Boone
Erin C. Boone
ADAnn Daly
Ann Daly
Evangelia Eirini TsermpiniEvangelia Eirini Tsermpini
Evangelia Eirini Tsermpini
AGAndrea Gaedigk
Andrea Gaedigk
The Pharmacogene Variation Consortium (PharmVar) serves as a global repository providing star (*) allele nomenclature for the polymorphic human CYP4F2 gene. CYP4F2 genetic variation impacts the metabolism of vitamin K, which is associated with warfarin dose requirements, and the metabolism of drugs, such as imatinib or fingolimod, and certain endogenous compounds including vitamin E and eicosanoids. This GeneFocus provides a comprehensive overview and summary of CYP4F2 genetic variation including the characterization of 14 novel star alleles, CYP4F2*4 through *17. A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided.